دورية أكاديمية
Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization.
| العنوان: | Outcomes in Patients with Macrotrabecular-Massive Subtype Hepatocellular Carcinoma Treated with Yttrium-90 Transarterial Radioembolization. |
|---|---|
| المؤلفون: | Balli HT; Department of Radiology, Adana, Turkey., Piskin FC; Department of Radiology, Adana, Turkey. Electronic address: ferhatcpiskin@gmail.com., Sozutok S; Department of Radiology, Adana, Turkey., Erdoğan KE; Department of Pathology, Cukurova University Medical School, Balcali Hospital, Adana, Turkey., Aikimbaev K; Department of Radiology, Adana, Turkey. |
| المصدر: | Journal of vascular and interventional radiology : JVIR [J Vasc Interv Radiol] 2024 Jul; Vol. 35 (7), pp. 998-1003. Date of Electronic Publication: 2024 Mar 26. |
| نوع المنشور: | Journal Article; Comparative Study |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society of Cardiovascular and Interventional Radiology Country of Publication: United States NLM ID: 9203369 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1535-7732 (Electronic) Linking ISSN: 10510443 NLM ISO Abbreviation: J Vasc Interv Radiol Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Reston, Va. : Society of Cardiovascular and Interventional Radiology, c1990- |
| مواضيع طبية MeSH: | Liver Neoplasms*/pathology , Liver Neoplasms*/radiotherapy , Liver Neoplasms*/mortality , Liver Neoplasms*/diagnostic imaging , Yttrium Radioisotopes*/administration & dosage , Carcinoma, Hepatocellular*/pathology , Carcinoma, Hepatocellular*/radiotherapy , Carcinoma, Hepatocellular*/mortality , Carcinoma, Hepatocellular*/diagnostic imaging , Embolization, Therapeutic*/mortality , Embolization, Therapeutic*/adverse effects , Radiopharmaceuticals*/administration & dosage , Radiopharmaceuticals*/adverse effects, Humans ; Male ; Female ; Aged ; Middle Aged ; Treatment Outcome ; Retrospective Studies ; Risk Factors ; Time Factors ; Tumor Burden |
| مستخلص: | Purpose: To compare the outcomes of yttrium-90 transarterial radioembolization (TARE) in patients with hepatocellular carcinoma (HCC) with and without macrotrabecular-massive (MTM) subtypes. Materials and Methods: Forty-one consecutive patients with HCC (male, 90.3%; mean age, 65.3 years [SD ± 10.7]) who underwent yttrium-90 TARE between September 2014 and January 2022 were grouped into the MTM-HCC (n = 17, 41.5%) and non-MTM-HCC (n = 24, 58.5%) groups based on their histopathological subtypes. Demographic, clinical, and radiological characteristics were compared. Survival, univariate, and multivariate analyses were performed, and prognostic factors were evaluated. Results: In MTM-HCC group, the rates of moderately to poorly differentiated tumors were significantly higher (13/17 vs 8/16, P = .007), and new intrahepatic/extrahepatic metastases were detected more frequently (12/17 vs 15/24, P = .038). Median overall survival (OS) in the cohort was 29 months (range, 17.1-40.9 months), whereas patients with MTM-HCC had a significantly shorter median OS (20 vs 44 months, P = .014). In univariate analysis, MTM-HCC subtype (hazard ratio [HR], 2.690; P = .021), the presence of satellite nodules (HR, 3.810; P = .004), and macrovascular invasion (HR, 3.321; P = .012) were identified as significant prognostic factors. In multivariate analysis, MTM-HCC subtype and macrovascular invasion were determined as independent poor prognostic factors (P = .038 and P = .012, respectively). Conclusions: In patients with HCC treated with yttrium-90 TARE, both the rates of moderately to poorly differentiated histopathological classes and the development of intrahepatic or extrahepatic metastases were significantly higher in the MTM-HCC subtype. OS was worse in patients with MTM-HCC, and macrovascular invasion and MTM-HCC subtype were identified as independent poor prognostic factors. (Copyright © 2024 SIR. Published by Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Yttrium Radioisotopes) 0 (Radiopharmaceuticals) 1K8M7UR6O1 (Yttrium-90) |
| تواريخ الأحداث: | Date Created: 20240328 Date Completed: 20240623 Latest Revision: 20240623 |
| رمز التحديث: | 20240624 |
| DOI: | 10.1016/j.jvir.2024.03.025 |
| PMID: | 38548131 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1535-7732 |
|---|---|
| DOI: | 10.1016/j.jvir.2024.03.025 |